Skip to content
VuFind
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文(繁體)
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
Հայերէն
Українська
Sámegiella
Монгол
Language
All Fields
Title
Author
Subject
Call Number
ISBN/ISSN
Tag
Find
Advanced
The impact of disease stage, i...
Cite this
Text this
Email this
Print
Export Record
Export to RefWorks
Export to EndNoteWeb
Export to EndNote
Permanent link
The impact of disease stage, indicated by number of previous oral antidiabetic agents, on the clinical benefits of liraglutide in the treatment of type 2 diabetes
Bibliographic Details
Main Authors:
Garber, A
,
Matthews, D
,
Zinman, B
,
Thomsen, AB
,
Falahati, A
,
Guerci, B
Format:
Conference item
Published:
2011
Holdings
Description
Similar Items
Staff View
Similar Items
Liraglutide, a human GLP-1 analogue, significantly improves beta cell function in subjects with type 2 diabetes
by: Matthews, DR, et al.
Published: (2008)
Liraglutide More Effectively Achieves a Composite Endpoint for A1C, SBP and Weight Change Than Other Diabetes Therapies
by: Zinman, B, et al.
Published: (2009)
Liraglutide, a human GLP-1 analogue, lowers HbA(1c) independent of weight loss
by: Schmidt, W, et al.
Published: (2009)
Liraglutide, a human GLP-1 analogue, reduces bodyweight in subjects with type 2 diabetes, irrespective of body mass index at baseline
by: Schmitz, O, et al.
Published: (2008)
Liraglutide is associated with a significantly greater improvement in glycaemic control than glimepiride in patients with highest baseline beta cell function
by: Matthews, DR, et al.
Published: (2009)